CheckMate 017: Nivolumab Superior to Docetaxel in Previously Treated Advanced Squamous NSCLC

May 29-June 2, 2015; Chicago, Illinois
Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.
Format: Microsoft PowerPoint (.ppt)
File Size: 610 KB
Released: June 1, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

Downloadable slideset reviewing the latest data informing optimal use of immune checkpoint inhibition for the treatment of pretreated SCLC, from Clinical Care Options (CCO)

Anna F. Farago, MD, PhD Taofeek K. Owonikoko, MD, PhD Released: July 9, 2020

In this slideset from Clinical Care Options, Jamie E. Chaft, MD outlines the current approach for the use of IO biomarkers and immunotherapy approaches for lung cancer.

Jamie E. Chaft, MD Released: July 9, 2020

Downloadable slideset reviewing the latest data informing optimal use of immune checkpoint inhibition for the treatment of SCLC, from Clinical Care Options (CCO)

Anna F. Farago, MD, PhD Taofeek K. Owonikoko, MD, PhD Released: July 9, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?